UAMS Osteoporosis Research Findings Published in Nature Communications

By Ben Boulden

Findings from a research effort led by Maria Almeida, Ph.D., an associate professor and researcher in the UAMS Center for Osteoporosis and Metabolic Bone Diseases, are published in the April edition of the scientific journal Nature Communications.

The research team includes Stavros Manolagas, M.D., Ph.D., director of the center; Robert Jilka, Ph.D.; Elena Ambrogini, M.D.; Robert Weinstein, M.D.; Haibo Zhao, M.D., Ph.D.; Charles  O’Brien, Ph.D.; Shoshana Bartell; Ha-Neui Kim; Li Han; and Serra Ucer.

The researchers used several mouse models with modified proteins so osteoclasts, the cells responsible for the resorption of bone, generate less reactive oxygen chemicals, also called reactive oxygen species. Bone resorption occurs when osteoclast cells break down the mineralized matrix to allow for old bone to be replaced with new one.

“We’ve shown that reactive oxygen species are important for the formation of osteoclasts and to control bone mass,” Almeida said. “Our findings indicate that if you can lower reactive oxygen species, then you can increase bone mass because you decrease the resorption of the bone.”

In the next phase of her research, Almeida and the other researchers will seek to learn more about how the reactive oxygen species control bone cells. Using antioxidants to reduce the presence of the species in osteoclasts can have negative side effects on other cells in the body. A better understanding of how reactive oxygen species work may enable future researchers to devise better treatments for osteoporosis with fewer side effects.

“We are looking for something that will work besides antioxidants that most of the cells can tolerate and that will still work to reduce these reactive oxygen species — a pill you can take to stop aging,” Almeida said. “During the aging process, common disease mechanisms can affect different organs like the brain, heart, liver and bones. We want to understand these common mechanisms so that by using one specific drug, it’s possible to treat many of these different things that occur with aging — for example, osteoporosis, arteriosclerosis and neural degeneration.”


UAMS is the state's only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; hospital; a main campus in Little Rock; a Northwest Arkansas regional campus in Fayetteville; a statewide network of regional campuses; and seven institutes: the Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine & Neurosciences Institute, Harvey & Bernice Jones Eye Institute, Psychiatric Research Institute, Donald W. Reynolds Institute on Aging, Translational Research Institute and Institute for Digital Health & Innovation. UAMS includes UAMS Health, a statewide health system that encompasses all of UAMS' clinical enterprise including its hospital, regional clinics and clinics it operates or staffs in cooperation with other providers. UAMS is the only adult Level 1 trauma center in the state. U.S. News & World Report named UAMS Medical Center the state's Best Hospital; ranked its ear, nose and throat program among the top 50 nationwide; and named six areas as high performing — COPD, colon cancer surgery, heart failure, hip replacement, knee replacement and lung cancer surgery. UAMS has 2,876 students, 898 medical residents and four dental residents. It is the state's largest public employer with more than 10,000 employees, including 1,200 physicians who provide care to patients at UAMS, its regional campuses, Arkansas Children's Hospital, the VA Medical Center and Baptist Health. Visit or Find us on Facebook, Twitter, YouTube or Instagram.